Dr. Clay Siegall: A Leader in Cancer Treatment

Clay Siegall is the founder, president, chief operating officer and chairman of the board of directors in Seattle Genetics. He founded the company in 1998 and proceeded to take on the positions which he currently holds. Under his able leadership, Seattle Genetics has grown to develop a wide range of antibody-based cancer treatments and therapies. One of these therapies is brentuximab vedotin, denoted as ADCETRIS to which the Foods and Drugs Administration (FDA) granted accelerated approval in 2011. Financially, Dr. Siegall has guided his company to attain its initial public offering (IPO) in 2001. The company has been able to secure over 675 million U.S dollars through private and public funding since it was founded in 1998.

Before ascending to his position in Seattle Genetics, Dr. Siegall had worked in different other health-related corporations in his younger years. He worked in the Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997 as a team member. He also worked with the National Cancer Institute, National Institutes of Health from 1988 to 1991. Before then, he had worked in Genetech, Biopharma, Curagen Corporation and Medimmune under different capacities. He is also a member of the board of directors for Alder BioPharmaceuticals, which is a privately owned biotechnology company based in Bothell, Washington. He has authored over 70 publications and is the sole holder of 15 patients.

Academically, Dr. Clay Siegall holds a Bachelor of Science Degree in Zoology, a Ph.D. in Genetics from the universities of Maryland and Washington respectively. He believes very firmly that the old cancer treatment methods such as systematic chemotherapy are all headed for absolute failure. He thinks that as the targeted therapies became better understood and appreciated for their value and efficacy, the prior therapies will be replaced by the more tolerable and more effective drugs under development. To benefit from this paradigm shift in cancer treatment, Dr. Siegall has worked hard to ensure that his company is in the forefront of developing these new forms of medication and therapies so that when the market is ready, they will become the absolute market leaders in cancer treatment. He believes that the sole secret to his success is hard work.

Oncotarget – The Journal of Research

Oncotarget is a medical journal published on a weekly basis with an open and free access. Oncotarget publications covers research and study of all fields of oncology. Oncotarget was established in the year 2010. Oncotarget has a fifty member editorial board. The editor-in-chief is Professor Mikhail Blagosklonny.

Oncotarget is also available on Dove Press.

Oncotarget’s sole mission is to make scientific results widely available and rapidly accessible. Oncotarget aims to maximize the impact of research via an insightful review. Oncotarget has produced several issues, each issue is easily and readily accessible online.

Oncotarget has an excellent editorial board comprising of fifty highly knowledgeable and successful professionals. Among them are Andrei V. Gudkov, Mikhail V. Blagosklonny, Cory Abate-Shen, Frederick Alt, Dario Altieri, Dafna Bar-Sagi, Jiri Bartek, Stephen Baylin, Joseph R. Bertino, Mina J. Bissell, Bruce Blazar, Kenneth Cowan, Carlo M. Croce, Chi Van Dang, Ronald A. DePinho, Brian J. Druker, Wafik S.El-Deiry, Michael A. Dyer, Andrew Feinberg, Dean W. Felsher, Antonio Giordano, Candace S Johnson, William G. Kaelin, Jr, Michael Karin, Scott E. Kern, Guido Kroemer, John S. Lazo, Arnold Levine, Michael P. Lisanti.

Oncotarget is a reliable publication that adheres strictly with the COPE Code of Conduct Best Practices Guidelines for Journal Editors and Code of Conduct for Journal Publishers. All editors of the medical journal also follow the best practice guidelines on ethical behavior and ICMJE’s Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals.

Download output styles at Endnote.com